Progress and Impact of 13 Years of the Global Programme to Eliminate Lymphatic Filariasis on Reducing the Burden of Filarial Disease

PLoS Neglected Tropical Diseases

Volumn 8, Issue 11, 2014, Pages

  Ramaiah, K D ^a   Ottesen, Eric A ^b,c  

^a Consultant on Lymphatic Filariasis ^*  (India)

^b The Task Force for Global Health   (United States)

^c RTI INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; ANTIFILARIAL AGENT; DIETHYLCARBAMAZINE; IVERMECTIN;

ADULT; ARTICLE; BRUGIA MALAYI; BRUGIA TIMORI; CHILD; DISEASE ELIMINATION; ENDEMIC DISEASE; HUMAN; HYDROCELE; LYMPHATIC FILARIASIS; LYMPHEDEMA; MATHEMATICAL MODEL; MICROFILARIA (NEMATODE LARVA); NONHUMAN; PARASITE LOAD; PARASITE PREVALENCE; PROGRAM EFFICACY; PROGRAM EVALUATION; PUBLIC HEALTH SERVICE; WUCHERERIA BANCROFTI; CHEMOPROPHYLAXIS; COST OF ILLNESS; DISEASE ERADICATION; ELEPHANTIASIS, FILARIAL; HEALTH; INTERNATIONAL COOPERATION; PREVENTIVE HEALTH SERVICE; PROCEDURES; STATISTICS AND NUMERICAL DATA; THEORETICAL MODEL;

CHEMOPREVENTION; COST OF ILLNESS; DISEASE ERADICATION; ELEPHANTIASIS, FILARIAL; FILARICIDES; GLOBAL HEALTH; HUMANS; INTERNATIONALITY; MODELS, THEORETICAL; PREVENTIVE HEALTH SERVICES;

EID: 84920419343     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0003319     Document Type: Article

References (83)

1. Michael E, Bundy DA, Grenfell BT, (1996) Re-assessing the global prevalence and distribution of lymphatic filariasis. Parasitology 112: 409–428.
2. Ottesen EA, Duke BO, Karam M, Behbehani K, (1997) Strategies and tools for the control/elimination of lymphatic filariasis. Bull World Health Org 75: 491–503.
3. Ottesen EA, (2000) The global programme to eliminate lymphatic filariasis. Trop Med Int Health 5: 591–594.
4. CDC (1993) Centre for Disease Control and Prevention (1993) Recommendations of the International Task Force for Disease Eradication. Morbidity and Mortality Weekly Report 42: RR 16.
5. De-Jian S, Xu-li D, Ji-hui D, (2013) The history of elimination of lymphatic filariasis in China. Infect Dis Poverty 2: 30.
6. http://www.filariasis.org/history.html Accessed on 2 January 2014.
7. http://www.who.int/lymphatic_filariasis/en/Accessed on 2 January 2014.
8. Stolk WA, de Vlas SJ, Habbema JDF, (2006) Advances and challenges in predicting the impact of lymphatic filariasis elimination programmes by mathematical modeling. Filaria J 5: 5.
9. http://www.who.int/neglected_diseases/preventive_chemotherapy/lf/en/. Accessed on 2 January 2014.
10. Michael E, Bundy DA, (1997) Global mapping of lymphatic filariasis. Parasitol Today 13: 472–476.
11. Gyapong J, Biswas G, Kumaraswami V, Ottesen EA, (2005) Treatment strategies that underpin the Global Programme to Eliminate Lymphatic Filariasis: 2-drug regimens utilizing albendazole with either DEC or ivermectin. Expert Opin Pharmacother 6: 179–200.
12. Das PK, Ramaiah KD, Vanamail P, Pani SP, Yuvaraj J, et al. (2001) Placebo-controlled community trial of four cycles of single dose diethylcarbamazine or ivermectin against Wuchereria bancrofti infection and transmission in India. Trans Roy Soc Trop Med Hyg 95: 336–341.
13. Bockarie MJ, Tisch DJ, Kastens W, Alexander ND, Dimber Z, et al. (2002) Mass treatment to eliminate filariasis in Papua New Guinea. N Engl J Med 347: 1841–1848.
14. Rajendran R, Sunish IP, Mani TR, Munirathinam A, Arunachalam N, et al. (2006) Community-based study to assess the efficacy of DEC plus ALB against DEC alone on bancroftian filarial infection in endemic areas in Tamil Nadu, south India. Trop Med Int Health 11: 851–861.
15. Ramzy RM, El Setouhy M, Helmy H, Ahmed ES, Abd Elaziz KM, et al. (2006) Effect of yearly mass drug administration with diethylcarbamazine and albendazole on bancroftian filariasis in Egypt: a comprehensive assessment. Lancet 367: 992–999.
16. Ramaiah KD, Das PK, Vanamail P, Pani SP, (2007) Impact of 10 years of diethylcarbamazine and ivermectin mass administration on infection and transmission of lymphatic filariasis. Trans R Soc Trop Med Hyg 101: 555–563.
17. Ramaiah KD, Vanamail P, Yuvaraj J, Das PK, (2011) Effect of annual mass administration of diethylcarbamazine and albendazole on bancroftian filariasis in five villages in south India. Trans R Soc Trop Med Hyg 105: 431–437.
18. Weil GJ, Kastens W, Susapu M, Laney SJ, Williams SA, et al. (2008) The impact of repeated rounds of mass drug administration with diethylcarbamazine plus albendazole on bancroftian filariasis in Papua New Guinea. PLoS Negl Trop Dis 2: e344.
19. Simonsen PE, Pedersen EM, Rwegoshora RT, Malecela MN, Derua YA, et al. (2010) Lymphatic filariasis control in Tanzania: effect of repeated mass drug administration with ivermectin and albendazole on infection and transmission. PLos Negl Trop Dis 4: e696.
20. Njenga SM, Mwandawiro CS, Wamae CN, Mukoko DA, Omar AA, et al. (2011) Sustained reduction in prevalence of lymphatic filariasis infection in spite of missed rounds of mass drug administration in an area under mosquito nets for malaria control. Parasit Vectors 4: 90.
21. King JD, Eigege A, Umaru J, Jip N, Miri E, et al. (2012) Evidence for stopping mass drug administration for lymphatic filariasis in some, but not all local government areas of Plateau and Nasarawa States, Nigeria. Am J Trop Med Hyg 87: 272–280.
22. de Kraker ME, Stolk WA, van Oortmarssen GJ, Habbema JD, (2006) Model-based analysis of trial data: microfilaria and worm-productivity loss after diethylcarbamazine-albendazole or ivermectin-albendazole combination therapy against Wuchereria bancrofti. Trop Med Int Health 11: 718–728.
23. Ramaiah KD, Vanamail P, Pani SP, Yuvaraj J, Das PK, (2002) The effect of six rounds of single dose mass treatment with diethylcarbamazine or ivermectin on Wuchereria bancrofti infection and its implications for lymphatic filariasis elimination. Trop Med Int Health 7: 767–774.
24. March HN, Laigret J, Kessel JF, Bambridge B, (1960) Reduction in the prevalence of clinical filariasis in Tahiti following adoption of a control program. Am J Trop Med Hyg 9: 180–184.
25. Ciferri F, Siliga N, Long G Kessel JF, (1969) A filariasis-control program in American Samoa. Am J Trop Med Hyg 18: 369–378.
26. Simonsen PE, Meyrowitsch DW, Makunde WH, Magnussen P, (1995) Selective diethylcarbamazine chemotherapy for control of Bancroftian filariasis in two communities of Tanzania: compared efficacy of a standard dose treatment and two semi-annual single dose treatments. Am J Trop Med Hyg 53: 267–272.
27. Meyrowitsch DW, Simonsen PE, Makunde WH, (1996) Mass diethylcarbamazine chemotherapy for control of bancroftian filariasis: comparative efficacy of standard treatment and two semi-annual single-dose treatments. Trans R Soc Trop Med Hyg 90: 69–73.
28. Meyrowitsch DW, Simonsen PE, (1998) Long-term effect of mass diethylcarbamazine chemotherapy on bancroftian filariasis, results at four years after start of treatment. Trans R Soc Trop Med Hyg 92: 98–103.
29. Yuvaraj J, Pani SP, Vanamail P, Ramaiah KD, Das PK, (2008) Impact of seven rounds of mass administration of diethylcarbamazine and ivermectin on prevalence of chronic lymphatic filariasis in south India. Trop Med Int Health 13: 737–742.
30. Partono F, Purnomo (1985) Combined low dosage and short term standard dose treatment with diethylcarbamazine to control Timorian filariasis. Acta Trop 42: 365–370.
31. Partono F, Maizels RM, Purnomo (1989) Towards a filariasis-free community: evaluation of filariasis control over an eleven year period in Flores, Indonesia. Trans R Soc Trop Med Hyg 83: 821–826.
32. Fan PC, Peng HW, Chen CC, (1995) Follow-up investigations on clinical manifestations after filariasis eradication by diethylcarbamazine medicated common salt on Kinmen (Quemoy) Islands, Republic of China. J Trop Med Hyg 98: 461–464.
33. Dunyo SK, Nkrumah FK, Simonsen PE, (2000) A randomized double-blind placebo-controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana. Trans R Soc Trop Med Hyg 94: 205–211.
34. Hairston NG, Jachowski LA, (1968) Analysis of the Wuchereria bancrofti population in the people of American Samoa. Bull World Health Org 38: 29–59.
35. Witt C, Ottesen EA, (2001) Lymphatic filariasis: an infection of childhood. Trop Med Int Health 6: 582–606.
36. Shenoy RK, Suma TK, Kumaraswami V, Rahmah N, Dhananjayan G, et al. (2009) Antifilarial drugs, in the doses employed in mass drug administrations by the global programme to eliminate lymphatic filariasis, reverse lymphatic pathology in children with Brugia malayi infection. Ann Trop Med Parasitol 103: 235–247.
37. Mladonicky JM, King JD, Liang JL, Chambers E, Pa'au M, et al. (2009) Assessing transmission of lymphatic filariasis using parasitologic, serologic, and entomologic tools after mass drug administration in American Samoa. Am J Trop Med Hyg 80: 769–773.
38. WHO (2006) World Health Organization. Weekly Epidemiological Record 81: 221–232.
39. World Health Organization (2012) Provisional strategy for interrupting Lymphatic filariasis transmission in loiasis-endemic countries, Report of the meeting on lymphatic filariasis, malaria and integrated vector management. Accra, Ghana, 5–9 March 2012. 2012. WHO/HTM/NTD/PCT/2012.6.
40. WHO (2001) World Health Organization. Weekly Epidemiological Record 76: 149–156.
41. Ramaiah KD, Ramu K, Kumar KN, Guyatt H, (1996) Epidemiology of acute filarial episodes caused by Wuchereria bancrofti infection in two rural villages in Tamil, Nadu, south India. Trans R Soc Trop Med Hyg 90: 639–643.
42. Gasarasi DB, Premji ZG, Mujinja PG, Mpembeni R, (2000) Acute adenolymphangitis due to bancroftian filariasis in Rufiji district, south east Tanzania. Acta Trop 75: 19–28.
43. WHO (2010) Lymphatic Filariasis. Progress Report 2000–2009 and Strategic Plan 2010–2020. WHO/HTM/NTD/PCT/2010.6
44. Ramaiah KD, Das PK, (2004) Mass drug administration to eliminate lymphatic filariasis in India. Trends Parasitol 20: 499–502.
45. Goldman AS, Guisinger VH, Aikins M, Amarillo ML, Belizario VY, et al. (2007) National mass drug administration costs for lymphatic filariasis elimination. PLoS Negl Trop Dis 1: e67.
46. Gustavsen KM, Bradley MH, Wright AL, (2009) GlaxoSmithKline and Merck: private-sector collaboration for the elimination of lymphatic filariasis. Ann Trop Med Parasitol 103 Suppl 1: S11–15.
47. WHO (1999) Building Partnerships for Lymphatic Filariasis. Strategic Plan WHO/FIL/99.198.
48. Dreyer G, Ottesen EA, Galdino E, Andrade L, Rocha A, et al. (1992) Renal abnormalities in microfilaremic patients with Bancroftian filariasis. Am J Trop Med Hyg 46: 745–751.
49. Gyapong JO, Gyapong M, Evans DB, Aikins MK, Adjei S, (1996) The economic burden of lymphatic filariasis in northern Ghana. Ann Trop Med Parasitol 90: 39–48.
50. Dreyer G, Noroes J, Figueredo-Silva J, Piessens WF, (2000) Pathogenesis of lymphatic disease in bancroftian filariasis: a clinical perspective. Parasitol Today 16: 544–548.
51. Ottesen EA, (1985) Efficacy of diethylcarbamazine in eradicating infection with lymphatic-dwelling filariae in humans. Rev Infect Dis 7: 341–356.
52. Ismail MM, Jayakody RL, Weil GJ, Nirmalan N, Jayasinghe KS, et al. (1998) Efficacy of single dose combinations of albendazole, ivermectin and diethylcarbamazine for the treatment of bancroftian filariasis. Trans R Soc Trop Med Hyg 92: 94–97.
53. Sasa (1976). Human Filariasis. A Global Survey of Epidemiology and Control. University Park Press, Baltimore, pp.819.
54. Akogun OB, Akogun MK, Apake E, Kale OO, (2011) Rapid community identification, pain and distress associated with lymphoedema and adenolymphangitis due to lymphatic filariasis in resource-limited communities of North-eastern Nigeria. Acta Trop 120 Suppl 1: S62–68.
55. Ramaiah KD, Ramu K, Guyatt H, Kumar KN, Pani SP, (1998) Direct and indirect costs of the acute form of lymphatic filariasis to households in rural areas of Tamil Nadu, south India. Trop Med Int Health 3: 108–115.
56. Babu BV, Nayak AN, (2003) Treatment costs and work time loss due to episodic adenolymphangitis in lymphatic filariasispatients in rural communities of Orissa, India. Trop Med Int Health 8: 1102–1109.
57. Ottesen EA, Hooper PJ, Bradley M, Biswas G, (2008) The global programme to eliminate lymphatic filariasis: health impact after 8 years. PLoS Negl Trop Dis 2: e317.
58. Ramaiah KD, Das PK, Appavoo NC, Ramu K, Augustin DJ, et al. (2000) A programme to eliminate lymphatic filariasis in Tamil Nadu state, India: compliance with annual single-dose DEC mass treatment and some related operational aspects. Trop Med Int Health 5: 842–847.
59. Ramaiah KD, Vijay Kumar KN, Chandrakala AV, Augustin DJ, Appavoo NC, et al. (2001) Effectiveness of community and health services-organized drug delivery strategies for elimination of lymphatic filariasis in rural areas of Tamil Nadu, India. Trop Med Int Health 6: 1062–1069.
60. Ramaiah KD, Vijay Kumar KN, Ravi R, Das PK, (2005) Situation analysis in a large urban area of India, prior to launching a programme of mass drug administrations to eliminate lymphatic filariasis. Ann Trop Med Parasitol 99: 243–252.
61. Ramaiah KD, Vijay Kumar KN, Hosein E, Krishnamoorthy P, Augustin DJ, et al. (2006) A campaign of “communication for behavioural impact” to improve mass drug administrations against lymphatic filariasis: structure, implementation and impact on people's knowledge and treatment coverage. Ann Trop Med Parasitol 100: 345–361.
62. Ramaiah KD, (2009) Lymphatic filariasis elimination programme in India: progress and challenges. Trends Parasitol 25: 7–8.
63. Haldar A, Mundle M, Haldar S, Biswas AK, Mitra SP, et al. (2001) Mass DEC campaign for filariasis in a hyper endemic district of West Bengal. J Commun Dis 33: 192–197.
64. Babu BV, Satyanarayana K, (2003) Factors responsible for coverage and compliance in mass drug administration during the programme to eliminate lymphatic filariasis in the East Godavari District, South India. Trop Doct 33: 79–82.
65. Babu BV, Kar SK, (2004) Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Trop Med Int Health 9: 702–709.
66. Regu KM, Showkath Ali MK, Rajendran R, Koya SM, Ganesh B, et al. (2006) Mass drug administration against lymphatic filariasis: experiences from Kozhikode district of Kerala State. J Commun Dis 38: 333–338.
67. Vaishnav KG, Patel IC, (2006) Independent assessment of Mass Drug Administration in filariasis affected Surat city. J Commun Dis 38: 149–154.
68. Showkath Ali MK, Rajendran R, Regu K, Mohanan MK, Dhariwal AC, et al. (2010) Study on the factors affecting the MDA programme in Kerala state. J Commun Dis 39: 51–56.
69. Lahariya C, Mishra A, (2008) Strengthening of mass drug administration implementation is required to eliminate lymphatic filariasis from India: an evaluation study. J Vector Borne Dis 45: 313–320.
70. Kumar P, Prajapati P, Saxena D, Kavishwar AB, Kurian G, (2008) An evaluation of coverage and compliance of mass drug administration 2006 for elimination of lymphatic filariasis in endemic areas of Gujarat. Indian J Community Med 33: 38–42.
71. Kumar A, Kumar P, Nagaraj K, Nayak D, Ashok L, Ashok K, (2009) A study on coverage and compliance of mass drug administration programme for elimination of filariasis in Udupi district, Karnataka, India. J Vector Borne Dis 46: 237–240.
72. Aswathy S, Beteena K, Leelamoni K, (2009) Mass drug administration against filariasis in India: perceptions and practices in a rural community in Kerala. Ann Trop Med Parasitol 103: 617–624.
73. Cantey PT, Rao G, Rout J, Fox LM, (2010) Predictors of compliance with a mass drug administration programme for lymphatic filariasis in Orissa State, India 2008. Trop Med Int Health 15: 224–231.
74. Cantey PT, Rout J, Rao G, Williamson J, Fox LM, (2010b) Increasing compliance with mass drug administration programs for lymphatic filariasis in India through education and lymphedema management programs. PLoS Negl Trop Dis 4: e728.
75. World Health Organization (2013) African Programme for Onchocerciasis Control: meeting of national onchocerciasis task forces, September 2013. World Health Organization. Weekly epidemiological record 50, 88: 533–544.
76. World Health Organization (2012) African Programme for Onchocerciasis Control (APOC); Country Profiles – Nigeria. Available: http://www.who.int/apoc/countries/nga/en/index.html. Accessed 05 September 2014.
77. Njepuome NA, Hopkins DR, Richards FO, JrAnagbogu IN, Pearce PO, et al. (2009) Nigeria's war on terror: fighting dracunculiasis, onchocerciasis, lymphatic filariasis, and schistosomiasis at the grassroots. Am J Trop Med Hyg 80: 691–698.
78. Okorie PN, Ademowo GO, Saka Y, Davies E, Okoronkwo C, et al. (2013) Lymphatic Filariasis in Nigeria; Micro-stratification Overlap Mapping (MOM) as a Prerequisite for Cost-Effective Resource Utilization in Control and Surveillance. PLoS Negl Trop Dis 7(9): e2416.
79. Kyelem D, Sanou S, Boatin B, Medlock J, Coulibaly S, Molyneux DH, (2003) Impact of long-term ivermectin (Mectizan) on Wuchereria bancrofti and Mansonella perstans infections in Burkina Faso: strategic and policy implications. Ann Trop Med Parasitol 97: 827–838.
80. Kyelem D, Medlock J, Sanou S, Bonkoungou M, Boatin B, Molyneux DH, (2005) Impact of long-term (14 years) bi-annual ivermectin treatment on Wuchereria bancrofti microfilaraemia. Trop Med Int Health 10: 1002–1004.
81. Richards FO, Emukah E, Graves PM, Nkwocha O, Nwankwo L, et al. (2013) Community-wide distribution of long-lasting insecticidal nets can halt transmission of lymphatic filariasis in southeastern Nigeria. Am J Trop Med Hyg 89: 578–587.
82. Kelly-Hope LA, Molyneux DH, Bockarie MJ, (2013) Can malaria vector control accelerate the interruption of lymphatic filariasis transmission in Africa; capturing a window of opportunity? Parasites & Vectors 6: 39.
83. Reimer LJ, Thomsen EK, Tisch DJ, Henry-Halldin CN, Zimmerman PA, Baea ME, Dagoro H, Susapu M, Hetzel MW, Bockarie MJ, Michael E, Siba PM, Kazura JW, (2013) Insecticidal bed nets and filariasis transmission in Papua New Guinea. New Engl J Med 369: 745–53.